Results of a preliminary study of the potential of vasodilators for improving thermotherapy of deep-seated tumours [printed with original paging at end of 2(2); omitted from Int J Hyperthermia 1986 Jan-Mar;2(1)].
Administration of the vasodilator hydralazine to a single mongrel dog with a transplanted, superficial transmissible venereal tumour in the abdomen permitted tumour-adjacent normal tissue temperature differences produced in local hyperthermia to be enhanced by nearly 2 degrees C. A preliminary study of tumour and normal tissue perfusion rate in the dog, employing the 15O-labelled water-positron emission tomography technique, suggested that administration of the vasodilator led to a significant reduction in the tumour perfusion rate, consistent with the observed tumour temperature enhancement. Computational studies with a multi-layer, one-dimensional cylindrical model of deep-tumour heating suggest that vasodilator-induced reductions of tumour perfusion rates could significantly increase deep tumour-superficial normal tissue temperature differences produced in deep-tumour thermotherapy.
D000818:Animals; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D004283:Dog Diseases / Q000188:drug therapy / Q000628:therapy; D004285:Dogs; D006830:Hydralazine / Q000627:therapeutic use*; D006979:Hyperthermia, Induced; D014685:Venereal Tumors, Veterinary / Q000188:drug therapy / Q000628:therapy*
D006830:Hydralazine